Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03083873 · ClinicalTrials.gov registry record · Phase 2
Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
A Phase 2 study, sponsored by Iovance Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT03083873 is a Phase 2 study that has completed, run by Iovance Biotherapeutics. The registered enrollment target is 64 participants.
The verdict
NCT03083873, a Phase 2 study, has completed, sponsored by Iovance Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
Multicenter, multicohort, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145/LN-145-S1) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Interventions
- BIOLOGICAL LN-145
- BIOLOGICAL LN-145-S1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-01-09 |
| Est. Completion | 2022-08-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03083873
The ClinicalTrials.gov registry entry for NCT03083873 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Iovance Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LN-145 is the first listed.
NCT03083873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03083873 about?
NCT03083873 is a clinical study titled "Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck". Multicenter, multicohort, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145/LN-145-S1) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the...
What is the current status of trial NCT03083873?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2017-01-09. Estimated completion is 2022-08-08.
What interventions are being tested in trial NCT03083873?
The interventions under investigation include: LN-145 (BIOLOGICAL), LN-145-S1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03083873?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.